235 related articles for article (PubMed ID: 36241168)
1. Immunogenicity and efficacy of COVID-19 vaccines in people living with HIV: a systematic review and meta-analysis.
Yin J; Chen Y; Li Y; Wang C; Zhang X
Int J Infect Dis; 2022 Nov; 124():212-223. PubMed ID: 36241168
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of COVID-19 vaccines among people living with HIV: A systematic review and meta-analysis.
Zhao T; Yang Z; Wu Y; Yang J
Epidemiol Infect; 2023 Sep; 151():e176. PubMed ID: 37704371
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 vaccine immunogenicity for people living with HIV: A systematic review and meta-analysis.
Søndergaard MH; Thavarajah JJ; Churchill Henson H; Wejse CM
HIV Med; 2024 Jan; 25(1):16-37. PubMed ID: 37731375
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis.
Lee ARYB; Wong SY; Chai LYA; Lee SC; Lee MX; Muthiah MD; Tay SH; Teo CB; Tan BKJ; Chan YH; Sundar R; Soon YY
BMJ; 2022 Mar; 376():e068632. PubMed ID: 35236664
[TBL] [Abstract][Full Text] [Related]
5. Seroconversion rate after COVID-19 vaccination in patients with solid cancer: A systematic review and meta-analysis.
Yin J; Chen Y; Li Y; Zhang X; Wang C
Hum Vaccin Immunother; 2022 Nov; 18(6):2119763. PubMed ID: 36161976
[TBL] [Abstract][Full Text] [Related]
6. Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV.
Corma-Gómez A; Fernández-Fuertes M; García E; Fuentes-López A; Gómez-Ayerbe C; Rivero-Juárez A; Domínguez C; Santos M; Viñuela L; Palacios R; Real LM; Rivero A; Macías J; Pineda JA; García F
Clin Microbiol Infect; 2022 Nov; 28(11):1492-1498. PubMed ID: 35640840
[TBL] [Abstract][Full Text] [Related]
7. Comparing Immune Responses to Inactivated Vaccines against SARS-CoV-2 between People Living with HIV and HIV-Negative Individuals: A Cross-Sectional Study in China.
Huang X; Yan Y; Su B; Xiao D; Yu M; Jin X; Duan J; Zhang X; Zheng S; Fang Y; Zhang T; Tang W; Wang L; Wang Z; Xu J
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215870
[TBL] [Abstract][Full Text] [Related]
8. Extending the dosing interval of COVID-19 vaccination leads to higher rates of seroconversion in people living with HIV.
Wang Y; Li J; Zhang W; Liu S; Miao L; Li Z; Fu A; Bao J; Huang L; Zheng L; Li E; Zhang Y; Yu J
Front Immunol; 2023; 14():1152695. PubMed ID: 36936952
[TBL] [Abstract][Full Text] [Related]
9. A tale of two conditions: when people living with HIV meet three doses of inactivated COVID-19 vaccines.
Tan Y; Zou S; Ming F; Wu S; Guo W; Wu M; Tang W; Liang K
Front Immunol; 2023; 14():1174379. PubMed ID: 37404815
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of inactivated SARS-CoV-2 vaccines in people living with HIV: A longitudinal cohort study.
Li J; Nie L; Guo C; Deng Y; Guo Q; Pang C; Xin R; Li J; Lu H; Huang C
J Med Virol; 2023 Dec; 95(12):e29334. PubMed ID: 38140842
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV.
Ao L; Lu T; Cao Y; Chen Z; Wang Y; Li Z; Ren X; Xu P; Peng M; Chen M; Zhang G; Xiang D; Cai D; Hu P; Shi X; Zhang D; Ren H
Emerg Microbes Infect; 2022 Dec; 11(1):1126-1134. PubMed ID: 35369854
[TBL] [Abstract][Full Text] [Related]
12. Humoral immune response to inactivated COVID-19 vaccination at the 3rd month among people living with HIV.
Wu S; Zou S; Ming F; Wu M; Guo W; Xing Z; Zhang Z; Liu J; Tang W; Liang K
BMC Infect Dis; 2023 Jan; 23(1):34. PubMed ID: 36670363
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and effectiveness of COVID-19 booster vaccination among people living with HIV: a systematic review and meta-analysis.
Cheng MQ; Li R; Weng ZY; Song G
Front Med (Lausanne); 2023; 10():1275843. PubMed ID: 37877024
[TBL] [Abstract][Full Text] [Related]
14. Seroconversion following the first, second, and third dose of SARS-CoV-2 vaccines in immunocompromised population: a systematic review and meta-analysis.
Mehrabi Nejad MM; Shobeiri P; Dehghanbanadaki H; Tabary M; Aryannejad A; Haji Ghadery A; Shabani M; Moosaie F; SeyedAlinaghi S; Rezaei N
Virol J; 2022 Aug; 19(1):132. PubMed ID: 35941646
[TBL] [Abstract][Full Text] [Related]
15. The effectiveness of the first dose COVID-19 booster vs. full vaccination to prevent SARS-CoV-2 infection and severe COVID-19 clinical event: a meta-analysis and systematic review of longitudinal studies.
Xu J; Lan X; Zhang L; Zhang X; Zhang J; Song M; Liu J
Front Public Health; 2023; 11():1165611. PubMed ID: 37325336
[TBL] [Abstract][Full Text] [Related]
16. Qualitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV.
Tuan JJ; Zapata H; Critch-Gilfillan T; Ryall L; Turcotte B; Mutic S; Andrews L; Roh ME; Friedland G; Barakat L; Ogbuagu O
HIV Med; 2022 Feb; 23(2):178-185. PubMed ID: 34632695
[TBL] [Abstract][Full Text] [Related]
17. The safety and immunogenicity of a two-dose schedule of CoronaVac, and the immune persistence of vaccination for six months, in people living with HIV: A multicenter prospective cohort study.
Wang Y; Qiao Y; Huo Y; Wang L; Liang S; Yu M; Lan X; Song M; Zhang X; Yan Y; Xu J
Front Immunol; 2023; 14():1129651. PubMed ID: 36993947
[TBL] [Abstract][Full Text] [Related]
18. Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count.
Antinori A; Cicalini S; Meschi S; Bordoni V; Lorenzini P; Vergori A; Lanini S; De Pascale L; Matusali G; Mariotti D; Cozzi Lepri A; Gallì P; Pinnetti C; Gagliardini R; Mazzotta V; Mastrorosa I; Grisetti S; Colavita F; Cimini E; Grilli E; Bellagamba R; Lapa D; Sacchi A; Marani A; Cerini C; Candela C; Fusto M; Puro V; Castilletti C; Agrati C; Girardi E; Vaia F;
Clin Infect Dis; 2022 Aug; 75(1):e552-e563. PubMed ID: 35366316
[TBL] [Abstract][Full Text] [Related]
19. Six-month humoral immune response to inactivated COVID-19 vaccine among people living with HIV.
Zou S; Guo W; Wu S; Ming F; Tan Y; Wu M; Tang W; Liang K
Front Immunol; 2022; 13():988304. PubMed ID: 36325346
[TBL] [Abstract][Full Text] [Related]
20. Dynamic immunogenicity after primary and booster inactivated SARS-CoV-2 vaccination in people living with HIV: A longitudinal observational study.
Lu T; Chen Z; Cao Y; Ao L; Li Z; Gu X; Ren X; Wang Y; Zhang G; Xiang D; Chen M; Cai D; Hu P; Zhang D; Peng M; Shi X; Ren H
J Med Virol; 2023 Apr; 95(4):e28730. PubMed ID: 37185852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
